Beyond traditional cancer treatment: Can we confront unmet n...

Surgery, chemotherapy, radiotherapy, and immunotherapy are designed to kill cancer, but what if we could control cancer?

ImmunityBio’s ANKTIVA & FDA Expanded Access: Transforming bl...

BioNTech’s ASCO 2025 oncology advances: New data on bispecif...

At ASCO 2025, BioNTech presented 7 abstracts on four selected pipeline candidates in mesothelioma, lung cancer, prostate cancer, and melanoma.

AbbVie’s ASCO 2025 ADC breakthroughs: Transforming oncology ...

ASCO 2025 insights: EVERSANA experts on AI, biomarkers, and ...

Servier’s ASCO 2025 data: Advancing IDH-mutated cancer treat...

At ASCO 2025, Servier’s Becky Martin discusses IDH-mutated cancers, including key insights on Tibsovo & Voranigo, and the implications for patients.